Taking Mongolian holistic concept as a guidance and dialectical treatment based on syndrome differentiation as a principle, to verify the effect of three Mongolian medicines to chronic pancreatitis (CP) model rats, AMURI-6, RUDA-6 and BATER-7 through pharmacological experiment and to select effective medicine to treat CP in clinic.Methods:80 Wistar rats were randomly divided into the 6 group. Rats in the model group and four dose groups were injected with Dibutyltin dichloride (DBTC) via the tail, and rats in the control group were injected with same amount of Dibutyltin dichloride solution via the tail. The model was made from the first day, and medicine was applied by intravenous administration twice a day. The model was tested14 days after modeling. All rats were put to death and sampled 28 days after modeling. Content of AMS and TNF-α were tested and HE staining histology was observed.Results:The general states of rats in the control group and the treatment groups were significantly better than those of rats in the model group. The levels of serum AMS and TNF-α of rats in the control group and the four treatment groups were significantly lower than those of rats in the model group (P<0.05). In the control group and the four treatment groups, the pathological evaluation，fibrosis degree and the extent of damage of the pancreas were significantly lower than those of the model group.Conclusion:The CP rat model made by injecting Dibutyltin dichloride (DBTC) via the tail was proved to be successfully set. Mongolian medicines, AMURI-6, RUDA-6 and BATER-7, may have the function of recovering part of pancreatic gland alveolus of the model group and reducing fibrous tissue among lobule. These medicines are effective for CP, which has a high clinical value in the treatment.